GlassScriptPhysician profile
Matthew D Ingham
NPI 1417242074
$9,742.48
in general payments reported to CMS, 2019-2025
26 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.44 · 2021: $404 · 2022: $3,616 · 2023: $1,165 · 2024: $1,521 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $2,095 · Travel and Lodging: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $2,094.88 |
| Travel and Lodging | $1,069.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,510.42 | 2022-2023 | Spaceoar Vue System - 10ml |
| Gyrus Acmi, INC. | $2,500.00 | 2025 | Soltive |
| Procept Biorobotics Corporation | $1,070.78 | 2022-2024 | Aquabeam System |
| Astellas Pharma US INC | $498.47 | 2021-2025 | Myrbetriq, Xtandi |
| Medtronic, INC. | $281.65 | 2025 | |
| Sumitomo Pharma America, INC. | $226.77 | 2024 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $208.17 | 2021-2023 | Prolaris |
| Merck Sharp & Dohme LLC | $188.44 | 2020-2024 | Keytruda, Lynparza |
| Convatec INC. | $157.84 | 2022-2023 | |
| Urogen Pharma, INC. | $144.00 | 2023-2024 | Jelmyto |
| Abbvie INC. | $142.85 | 2020-2024 | |
| Endo Pharmaceuticals INC. | $99.71 | 2022-2023 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $96.57 | 2022-2024 | Erleada |
| Tempus Ai, INC | $84.18 | 2024-2025 | Xt Cdx |
| Coloplast Corp | $77.44 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $74.20 | 2023-2024 | Illuccix |
| Acerus Pharmaceuticals Corporation | $74.05 | 2021-2022 | |
| Teleflex LLC | $70.21 | 2021 | |
| Urovant Sciences INC | $60.52 | 2022 | |
| Ferring Pharmaceuticals INC. | $51.66 | 2024 | Adstiladrin |
| Myovant Sciences INC. | $27.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.52 | 2020 | |
| Blue Earth Diagnostics | $23.28 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $21.34 | 2025 | Bard Urinary Drainage Bag |
| Axonics, INC. | $14.37 | 2021 | |
| Photocure INC | $14.27 | 2025 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.